• Merck will present new oral HIV treatment and prevention data at HIV Glasgow 2026, Nov. 8-11 in Glasgow, Scotland.
• Once-weekly islatravir/lenacapavir maintained viral suppression in previously presented Phase 3 findings; upcoming analyses will examine patient subgroups and treatment experiences.
• The FDA accepted two IDVYNSO supplemental applications covering previously untreated adults and longer-term data, with decisions due April 22, 2027.
• Once-daily IDVYNSO presentations will cover resistance, weight and patient-reported outcomes from Phase 3 studies.
• Adult enrollment is complete in both Phase 3 trials of once-monthly HIV prevention pill alimatravir; participant demographics will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102203384) on November 02, 2026, and is solely responsible for the information contained therein.